Last $3.72 USD
Change Today -0.17 / -4.37%
Volume 602.6K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Snapshot

Open
$3.90
Previous Close
$3.89
Day High
$3.92
Day Low
$3.70
52 Week High
01/17/14 - $7.45
52 Week Low
04/15/14 - $3.20
Market Cap
258.8M
Average Volume 10 Days
986.7K
EPS TTM
$-0.73
Shares Outstanding
69.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROGENICS PHARMACEUTICALS (PGNX)

progenics pharmaceuticals (PGNX) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. It also develops Relistor-oral that is in Phase III testing for the treatment of OIC. In addition, the company’s clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide other than Japan; and collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

69 Employees
Last Reported Date: 03/13/14
Founded in 1986

progenics pharmaceuticals (PGNX) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $672.8K
Founder and Vice Chairman
Total Annual Compensation: $224.5K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $292.1K
Senior Vice President of Medical Affairs & Cl...
Total Annual Compensation: $480.9K
Vice President of Regulatory Affairs
Total Annual Compensation: $341.5K
Compensation as of Fiscal Year 2012.

progenics pharmaceuticals (PGNX) Key Developments

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals, Inc. Announce the Acceptance of Submission to Expand the Use of RELISTOR in Chronic Non-Cancer Pain by the European Medicines Agency

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals, Inc. announced that the submission to the European Medicines Agency (EMA) of RELISTOR(methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, has been accepted for review. If approved, this will add to the current marketing authorization in the European Union (EU), which allows for the use of RELISTOR in advanced illness patients. The marketing of RELISTOR for the treatment of OIC in advanced illness patients was approved in the European Union in 2008, and is currently approved in more than 50 countries. RELISTOR remains the only single agent product approved for the treatment of OIC in the EU. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic pain.

Progenics Pharmaceuticals, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 10:00 AM

Progenics Pharmaceuticals, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 10:00 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director, Member of Science & Technology Committee and Member of Strategy & External Technology Subcommittee.

Progenics Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Initiates Clinical Development of Small Molecule Targeted Therapeutic

Progenics Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of $2,968,000 against $8,885,000 a year ago, resulting primarily from prior year partnering transactions. Operating loss was $8,923,000 against $341,000 a year ago. Net loss before provision for income taxes was $8,913,000 against $324,000 a year ago. Net loss was $8,551,000 against $324,000 a year ago. Net loss per basic and diluted share was $0.14 against $0.01 a year ago. For the year, the company reported total revenues of $7,862,000 against $14,048,000 a year ago. Operating loss was $42,980,000 against $35,491,000 a year ago. Net loss before provision for income taxes was $42,934,000 against $35,431,000 a year ago. Net loss was $42,572,000 against $35,431,000 a year ago. Net loss per basic and diluted share was $0.76 against $1.02 a year ago. The company announced that it is initiating clinical development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical for the treatment of prostate cancer. Memorial Sloan Kettering Cancer Center, a member of the Prostate Cancer Clinical Trials Consortium, has been designated as the principal site for the phase 1 study. Michael J. Morris, M.D., Associate Attending Physician in the Genitourinary Oncology Service at Memorial Sloan Kettering and one of the prostate cancer experts, will act as the principal investigator for the company-sponsored clinical trial. The phase 1 study is expected to commence following the submission of an investigational new drug application later 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $3.72 USD -0.17

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.80 USD +0.02
Cell Therapeutics Inc $3.18 USD -0.15
Rigel Pharmaceuticals Inc $3.21 USD -0.21
Sucampo Pharmaceuticals Inc $6.76 USD -0.10
Wyeth Ltd 860.15 INR +3.90
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 30.1x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit www.progenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.